GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Avalyn Pharma Inc. Common Stock AVLN · USD

US listing · 🇺🇸 United States

Compare

29.50

+1.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Avalyn Pharma Inc. Common Stock

Its shares trade under the ticker AVLN. It has been listed since 30 April 2026.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
30 Apr 2026
Head office
105 W FIRST ST., BOSTON, MA, 02127
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Operates as a clinical-stage biopharmaceutical company focused on inhaled medicines for rare respiratory diseases.
  • Develops inhaled formulations of oral medicines directly targeting the lungs for treatment.
  • Current pipeline specifically targets pulmonary fibrosis with products AP01, AP02, and AP03.

Weaknesses

  • Sector and industry are listed as unknown in the provided information.
  • IPO date is set for 2026-04-30, indicating future market entry.
  • Formerly known as Genoa Pharmaceuticals, Inc., suggesting a rebranding history.

Opportunities

  • Potential market for inhaled formulations of oral medicines in treating rare respiratory diseases.
  • Focus on pulmonary fibrosis could align with growing treatment needs for interstitial lung diseases.
  • Rebranding from Genoa Pharmaceuticals, Inc. may signal strategic shifts to attract investors.

Threats

  • Uncertainty around sector and industry classification may affect investor confidence.
  • IPO scheduled for 2026-04-30, which could be delayed or face market volatility.
  • Dependence on a narrow pipeline focused on pulmonary fibrosis may limit diversification.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.